{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:59:23Z","timestamp":1792400363684,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.rmed.2023.107374","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:12:21Z","timestamp":1690837941000},"page":"107374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil"],"prefix":"10.1016","volume":"218","author":[{"given":"Chad E.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kingrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Zolty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Melendres-Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-4193","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-1707","authenticated-orcid":false,"given":"Jean M.","family":"Elwing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-598X","authenticated-orcid":false,"given":"Dana","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-6570","authenticated-orcid":false,"given":"Eric","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-7160","authenticated-orcid":false,"given":"Scott","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-8949","authenticated-orcid":false,"given":"Claire M.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Oudiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.rmed.2023.107374_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.rmed.2023.107374_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2023.107374_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2023.107374_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.rmed.2023.107374_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.prostaglandins.2013.07.001","article-title":"A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor","volume":"107","author":"Benyahia","year":"2013","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.rmed.2023.107374_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.prostaglandins.2015.04.007","article-title":"The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors","volume":"120","author":"Clapp","year":"2015","journal-title":"Prostag. Other Lipid Mediat."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211052228","article-title":"Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 \u03bcg (nine breaths) four times daily","volume":"11","author":"Shapiro","year":"2021","journal-title":"Pulm. Circ."},{"issue":"6","key":"10.1016\/j.rmed.2023.107374_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107374_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J. Heart Lung Transplant."},{"issue":"9","key":"10.1016\/j.rmed.2023.107374_bib10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","article-title":"Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials","volume":"30","author":"Benza","year":"2011","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.rmed.2023.107374_bib11","unstructured":"Clinical Pharmacology and Biopharmaceutics reviews. Center for Drug Evaluation and Research, 2011. Vol Reference ID:3198107."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib12","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.healun.2013.01.975","article-title":"Impact of parenteral treprostinil dosing in pulmonary arterial hypertension","volume":"32","author":"Preston","year":"2013","journal-title":"J. Heart Lung Transplant."},{"issue":"5","key":"10.1016\/j.rmed.2023.107374_bib13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.rmed.2023.107374_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1164\/rccm.201602-0274LE","article-title":"Novel analysis of the oral treprostinil combination therapy trial data","volume":"193","author":"White","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2023.107374_bib15","series-title":"Pulmonary Hypertension","article-title":"Dose-response relationship of oral treprostinil for secondary endpoints in the FREEDOM-EV study","author":"White","year":"2019"},{"issue":"3","key":"10.1016\/j.rmed.2023.107374_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020923956","article-title":"Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations","volume":"10","author":"Ramani","year":"2020","journal-title":"Pulm. Circ."},{"issue":"6","key":"10.1016\/j.rmed.2023.107374_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2023.107374_bib18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2023.107374_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107374_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib21","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/j.healun.2014.01.919","article-title":"Rapid inpatient titration of intravenous treprostinil for severe pulmonary arterial hypertension","volume":"33","author":"Hansen","year":"2014","journal-title":"J. Heart Lung Transplant."},{"issue":"6","key":"10.1016\/j.rmed.2023.107374_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000450759","article-title":"Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial","volume":"92","author":"Gr\u00fcnig","year":"2016","journal-title":"Respiration"},{"issue":"7","key":"10.1016\/j.rmed.2023.107374_bib23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1164\/rccm.202109-2079PP","article-title":"Aggressive afterload lowering to improve the right ventricle: a new target for medical therapy in pulmonary arterial hypertension?","volume":"205","author":"Vizza","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107374_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.healun.2016.06.019","article-title":"Transition from parenteral to oral treprostinil in pulmonary arterial hypertension","volume":"36","author":"Chakinala","year":"2017","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"10.1016\/j.rmed.2023.107374_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018770654","article-title":"Dosing characteristics of oral treprostinil in real-world clinical practice","volume":"8","author":"Balasubramanian","year":"2018","journal-title":"Pulm. Circ."},{"issue":"2","key":"10.1016\/j.rmed.2023.107374_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-Based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2023.107374_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.rmed.2023.107374_bib28","unstructured":"Orenitram (treprostinil) [package insert]. Research Triangle Park, NC: United Therapeutics Corporation, 2013. Revised November 2020."},{"issue":"1","key":"10.1016\/j.rmed.2023.107374_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.rmed.2023.107374_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2023.107374_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med. Sci. Sports Exerc."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00127113","article-title":"emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension","volume":"43","author":"Yorke","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2023.107374_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.apnr.2014.04.001","article-title":"Development and initial psychometric properties of the pulmonary arterial hypertension symptom Scale (PAHSS)","volume":"28","author":"Matura","year":"2015","journal-title":"Appl. Nurs. Res."},{"key":"10.1016\/j.rmed.2023.107374_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcome"},{"key":"10.1016\/j.rmed.2023.107374_bib35","unstructured":"ADAPT - A patient registry of the real-world use of Orenitram. July 2, 2017. Accessed December 10, 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03045029."},{"key":"10.1016\/j.rmed.2023.107374_bib36","first-page":"A3811","article-title":"Real-world transitions from parenteral, inhaled, and oral prostacyclin-class therapies to oral treprostinil: interim data from the ADAPT registry","volume":"201","author":"Sahay","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2019.08.1494","article-title":"Successful transition from parenteral to oral treprostinil within 24 hours in pulmonary arterial hypertension","volume":"156","author":"Ali","year":"2019","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib38","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1016\/j.healun.2018.01.1289","article-title":"Rapid transition from parenteral to oral treprostinil in pulmonary hypertension is feasible and safe: a retrospective cohort study","volume":"37","author":"Jarrett","year":"2018","journal-title":"J. Heart Lung Transplant."},{"issue":"4","key":"10.1016\/j.rmed.2023.107374_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018797270","article-title":"Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension","volume":"8","author":"Maestas","year":"2018","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.rmed.2023.107374_bib40","article-title":"The rapid initiation, titration, and transition from intravenous to oral treprostinil in a patient with severe pulmonary arterial hypertension","volume":"2015","author":"Gleason","year":"2015","journal-title":"Case Rep Pulmonol"},{"key":"10.1016\/j.rmed.2023.107374_bib41","first-page":"A3823","article-title":"Rapid initiation, titration, and transition from IV to oral treprostinil: a retrospective study","volume":"201","author":"Chin","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2023.107374_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0091270004264638","article-title":"Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"14","key":"10.1016\/j.rmed.2023.107374_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11144034","article-title":"Risk stratification of patients with pulmonary arterial hypertension: the role of echocardiography","volume":"11","author":"Mercurio","year":"2022","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.rmed.2023.107374_bib44","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","article-title":"Tricuspid annular displacement predicts survival in pulmonary hypertension","volume":"174","author":"Forfia","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107374_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005771","article-title":"Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with validated models","volume":"10","author":"Amsallem","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.rmed.2023.107374_bib46","unstructured":"A study of a mean pulmonary artery pressure-targeted approach with earlyand rapid treprostinil therapy to reverse right ventricular remodeling in Participants with pulmonary arterial hypertension (ARTISAN). January 24, 2022. Accessed October 28, 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05203510."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:39:38Z","timestamp":1762033178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123002627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":46,"alternative-id":["S0954611123002627"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107374","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107374"}}